Kennedy Jr. wants to overhaul an obscure but vital program that underpins the nation’s childhood immunization system.

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

Merck & Co. Inc. closed 36.67% below its 52-week high of $128.73, which the company reached on July 26th.

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading ...

From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Data suggest that OSA diagnoses were associated with an increased risk for physical and psychological problems in active-duty ...

Dramatic changes to the Vaccine Injury Compensation Program risk driving drugmakers from the market, threatening access to shots.

The rally came despite a broader market volatility during the period, largely due to global trade worries over the United States’ imposition of tariffs against its trading partners, with China ...

One study reported 8 live births from 22 women with pathogenic mtDNA variants who underwent mitochondrial donation through pronuclear transfer. None had signs of mitochondrial disease and heteroplasmy ...